التفاصيل البيبلوغرافية
| العنوان: |
Crizotinib targets in glioblastoma stem cells. |
| المؤلفون: |
Junca, Audelaure, Villalva, Claire, Tachon, Gaëlle, Rivet, Pierre, Cortes, Ulrich, Guilloteau, Karline, Balbous, Anaïs, Godet, Julie, Wager, Michel, Karayan‐Tapon, Lucie |
| المصدر: |
Cancer Medicine; Nov2017, Vol. 6 Issue 11, p2625-2634, 10p |
| مصطلحات موضوعية: |
GLIOBLASTOMA multiforme treatment, CRIZOTINIB, IMMUNOHISTOCHEMISTRY, NUCLEOTIDE sequencing, GENETIC mutation, THERAPEUTICS |
| مستخلص: |
Glioblastoma stem cells (GSCs) are believed to be involved in the mechanisms of tumor resistance, therapeutic failures, and recurrences after conventional glioblastoma therapy. Therefore, elimination of GSCs might be a prerequisite for the development of successful therapeutic strategies. ALK, ROS1, and MET are targeted by Crizotinib, a tyrosine kinase inhibitor which has been approved for treatment of ALK-rearranged non-small-cell lung cancer. In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise. Fluorescent in situ hybridization (FISH), Sanger's direct sequencing, and immunohistochemistry were used to screen genomic rearrangements (or amplifications), genomic mutations, and protein expression, respectively. The immunohistochemical and FISH studies revealed no significant dysregulation of ROS1 in GSCs and associated tumors. Neither amplification nor polysomy of ALK was observed in GSC, but weak overexpression was detected by IHC in three of nine GSCs. Similarly, no MET amplification was found by FISH but three GSCs presented significant immunohistochemical staining. No ALK or MET mutation was found by Sanger's direct sequencing. In this study, we show no molecular rearrangement of ALK, ROS1, and MET that would lead us not to propose, as a valid strategy, the use of crizotinib to eradicate GSCs. However, MET was overexpressed in all GSCs with mesenchymal subtype and three GSCs presented an overexpression of ALK. Therefore, our study corroborates the idea that MET and ALK may assume a role in the tumorigenicity of GSC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder